• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors

    3/2/22 4:30:00 PM ET
    $MASS
    $RGEN
    Industrial Machinery/Components
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MASS alert in real time by email

    908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation (NASDAQ:RGEN), to serve on its Board of Directors effective immediately.

    Mr. Hunt brings a deep understanding of the bioprocessing market, with more than 20 years of life sciences management experience. He joined Repligen in 2014 as Chief Operating Officer and was promoted to his current role a year later. Mr. Hunt previously was President of Bioproduction at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. From 2000 to 2008, he was with Applied Biosystems as Senior Director of Pharma Programs where he launched the pharma analytics business that in 2008 became part of the bioproduction platform at Life Technologies.

    "I am delighted to welcome Tony to the 908 Devices' Board of Directors," said Kevin Hrusovsky, Chairman of 908 Devices. "Tony brings extensive market experience and valuable strategic insight into biopharmaceutical development and production. His significant track record of evaluating inorganic growth opportunities will also be an important addition to our Board."

    "I am honored to join the 908 Devices Board at this exciting stage of the company's journey," said Mr. Hunt. "The 908 Devices technology platform has tremendous potential to help researchers bring new therapeutics to market faster, and I look forward to partnering with the company's leadership team to unlock this capability."

    "One of our key priorities is to create a comprehensive bioanalytics platform from biotherapeutic development through production," said Kevin J. Knopp, CEO and co-founder of 908 Devices. "Tony's wealth of knowledge and experience in downstream bioproduction workflows will be invaluable as we do so."

    For more information, visit www.908devices.com.

    About 908 Devices

    908 Devices Inc. (NASDAQ:MASS) is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company's devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation and machine learning.

    Forward Looking Statements

    This press release includes "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding plans to develop a comprehensive bioanalytics platform and other strategic objectives. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under "Risk Factors" and elsewhere in the Company's filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in the Company's annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220302005796/en/

    Get the next $MASS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MASS
    $RGEN

    CompanyDatePrice TargetRatingAnalyst
    Repligen Corporation
    $RGEN
    4/29/2025$160.00Peer Perform → Outperform
    Wolfe Research
    Repligen Corporation
    $RGEN
    3/18/2025$155.00In-line
    Evercore ISI
    Repligen Corporation
    $RGEN
    2/10/2025$200.00Buy
    TD Cowen
    Repligen Corporation
    $RGEN
    12/17/2024$165.00Hold
    Canaccord Genuity
    Repligen Corporation
    $RGEN
    11/14/2024Peer Perform
    Wolfe Research
    908 Devices Inc.
    $MASS
    11/13/2024$12.00 → $4.00Outperform → Market Perform
    Leerink Partners
    Repligen Corporation
    $RGEN
    8/28/2024$180.00Overweight
    Wells Fargo
    Repligen Corporation
    $RGEN
    6/26/2024$180.00 → $155.00Hold → Buy
    Deutsche Bank
    More analyst ratings

    $MASS
    $RGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Romanian Customs Authority Adopts 908 Devices' MX908 for Border Security Operations

      The handheld mass spectrometers are now in active use for trace detection and identification of drugs and explosives for customs and border patrol applications 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announced that the Romanian Customs Authority has fully deployed 27 MX908 devices across its border operations. The units were delivered earlier this year and are now actively supporting frontline officers with real-time identification of trace chemicals, enhancing the country's ability to monitor cross-border movement and investigate suspicious substances with speed and precision. "We have already experienced the benefits of the MX

      5/28/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

      WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related reporting framework disclosures. Themed "Perspectives on Progress", this report communicates the company's progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways. Also included in the 2024 Corporate Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and two

      5/27/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen Corporation to Present at William Blair Growth Conference

      WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3rd at 1:20 p.m. CT. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen CorporationRepligen Corporation is a global

      5/22/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MASS
    $RGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      11/14/24 5:11:18 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      11/14/24 4:25:10 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Repligen Corporation

      SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

      11/14/24 1:22:37 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MASS
    $RGEN
    Financials

    Live finance-specific insights

    See more

    $MASS
    $RGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MASS
    $RGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • 908 Devices Reports First Quarter 2025 Financial Results and Reiterates 2025 Revenue Outlook

      Revenue from continuing operations grew 59% compared to prior year, driven by an increase in product and service revenue 908 Devices Inc. (NASDAQ:MASS) a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2025. "We are off to a strong start in 2025, with first-quarter revenue exceeding our expectations and the transformation to 908 Devices 2.0 already delivering both top-line growth and meaningful cost reductions," said Kevin J. Knopp, CEO and Co-founder. "With a sharpened focus, a strengthened financial position, and macro trends in

      5/13/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Repligen Reports First Quarter 2025 Financial Results

      Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growthOrders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic revenue guidance of 9.5% - 13.5% WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025. Olivier Loeillot, President and Chief Executive Officer

      4/29/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen to Report First Quarter 2025 Financial Results

      WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2025. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company

      4/15/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Knopp Kevin J. bought $66,596 worth of shares (15,000 units at $4.44), increasing direct ownership by 2% to 722,733 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/19/25 4:37:42 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Director Spoto Mark bought $42,850 worth of shares (10,000 units at $4.29), increasing direct ownership by 19% to 62,971 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/15/25 4:52:08 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • President and CEO Knopp Kevin J. bought $64,788 worth of shares (15,000 units at $4.32), increasing direct ownership by 2% to 707,733 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/14/25 4:28:02 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Repligen upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Repligen from Peer Perform to Outperform and set a new price target of $160.00

      4/29/25 2:20:14 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Repligen with a new price target

      Evercore ISI initiated coverage of Repligen with a rating of In-line and set a new price target of $155.00

      3/18/25 7:55:20 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TD Cowen initiated coverage on Repligen with a new price target

      TD Cowen initiated coverage of Repligen with a rating of Buy and set a new price target of $200.00

      2/10/25 7:05:45 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MASS
    $RGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Repligen Appoints Jacob Johnson As Vice President Investor Relations

      WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team's engagement with the investment community, reporting to the company's Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector. Mr. Garland commented, "Jacob is a terrific addition to the Repligen team, bringing a broad understanding of the bioprocessing tools space, the markets we serve and the growth driver

      4/8/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

      BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is

      12/16/24 8:11:00 AM ET
      $BLFS
      $RGEN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • 908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of responsibility, including Special Agent in Charge of the Los Angeles Field Division from 1998 to 2003, Deputy Administrator (nominated by President Bush) from 2003 to 2007, Acting Administrator from 2007 to 2010, and Admini

      6/25/24 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    $RGEN
    SEC Filings

    See more
    • SEC Form SD filed by 908 Devices Inc.

      SD - 908 Devices Inc. (0001555279) (Filer)

      5/28/25 7:00:23 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Repligen Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - REPLIGEN CORP (0000730272) (Filer)

      5/15/25 4:15:37 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by 908 Devices Inc.

      SCHEDULE 13G/A - 908 Devices Inc. (0001555279) (Subject)

      5/15/25 10:52:40 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    $RGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Barthelemy Nicolas was granted 973 shares, increasing direct ownership by 28% to 4,441 units (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      5/21/25 3:00:13 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Konstantinov Konstantin was granted 973 shares, increasing direct ownership by 51% to 2,894 units (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      5/19/25 8:26:29 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Muir Glenn P was granted 973 shares, increasing direct ownership by 3% to 33,256 units (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      5/19/25 8:19:08 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care